Key result
Abciximab therapy with low-dose heparin reduced the need for unplanned coronary stent deployment during percutaneous coronary intervention compared to placebo (9.0% vs 13.7%; P=0.001).
Why the study?
Does abciximab and low-dose heparin reduce the need for unplanned coronary stent deployment and adverse outcomes in patients undergoing percutaneous coronary intervention?
RCT (n=2,792)
Double-blind
randomized
Does abciximab and low-dose heparin reduce the need for unplanned coronary stent deployment and adverse outcomes in patients undergoing percutaneous coronary intervention?
Absolute Event Rate: 9% vs 13.7%
p-value: p=0.001
Abciximab therapy with low-dose heparin during percutaneous coronary intervention reduces the need for unplanned stent deployment and improves clinical outcomes without increasing bleeding risk.
No takes yet. Share an insight, caveat, or question.
Abciximab with low-dose heparin may reduce unplanned stenting in PCI; extends evidence for GP IIb/IIIa inhibitors improving procedural success.
Kereiakes et al. (1998) conducted an RCT in Percutaneous coronary intervention (n=2,792). Abciximab and low-dose, weight-adjusted heparin vs. Placebo and standard-dose heparin was evaluated on Unplanned coronary stent deployment (p=0.001). Abciximab therapy with low-dose heparin reduced the need for unplanned coronary stent deployment during percutaneous coronary intervention compared to placebo (9.0% vs 13.7%; P=0.001).